Info: Read More
  • 中药标准品生产商,产品定制服务
  • Science | Nature | Cell | View More


    Gambogic acid

    产品编号 CFN90172
    CAS编号 2752-65-0
    分子式 = 分子量 C38H44O8 = 628.75
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Miscellaneous
    植物来源 The herbs of Garcinia hanburyi Hook. f.
    产品名称 产品编号 CAS编号 包装 QQ客服
    藤黄酸 CFN90172 2752-65-0 10mg QQ客服:1457312923
    藤黄酸 CFN90172 2752-65-0 20mg QQ客服:1457312923
    藤黄酸 CFN90172 2752-65-0 50mg QQ客服:1457312923
    藤黄酸 CFN90172 2752-65-0 100mg QQ客服:1457312923
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: 或

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.

    PMID: 30417089
  • Gyeongsang National University (Korea)
  • University of British Columbia (Canada)
  • Indian Institute of Science (India)
  • Aveiro University (Portugal)
  • Guangzhou Institutes of Biomedicine and Health (China)
  • University of Indonesia (Indonesia)
  • University of Hawaii Cancer Center (USA)
  • Korea Food Research Institute(KFRI) (Korea)
  • Universidade do Porto (Portugal)
  • Johannes Gutenberg University Mainz (JGU) (Germany)
  • Sanford Burnham Prebys Medical Discovery Institute (USA)
  • Regional Crop Research Institute (Korea)
  • Osmania University (India)
  • Warszawski Uniwersytet Medyczny (Poland)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Nat Prod Sci.2014, 20(3):182-190
  • Evid Based Complement Alternat Med.2016, 2016:1230294
  • Chem Biol Interact.2016, 258:59-68
  • Int J Mol Sci.2017, 18(12)
  • Sci Rep.2017, 7:467-479
  • Pharmacol Rep.2018, 70(6):1195-1201
  • Front Pharmacol.2018, 9:236
  • Cell Death Dis.2019, 10(12):882
  • Clin Transl Oncol.2019, 10.1007
  • Mol Microbiol.2019, 112(1):317-332
  • ACS Chem Biol.2019, 14(5):873-881
  • J Ethnopharmacol.2019, 244:112074
  • Int J Food Sci Nutr.2019, 70(7):825-833
  • J Nat Prod.2019, 82(4):1002-1008
  • Biochem Biophys Res Commun.2020, 522(4):1052-1058
  • Crystals2020, 10(3), 206.
  • Nutrients.2020, 12(3):595.
  • Pharmaceutics.2020, 12(9):882.
  • Molecules.2020, 25(15):3353.
  • Horticulturae2020, 6(4),76.
  • J Agric Food Chem.2020, 68(51):15164-15175
  • Pharmacol Rep.2020, 72(2):472-480.
  • Nutraceutical Research . 2021, 19(1),p90-105.
  • ...
  • 生物活性
    Description: Gambogic acid is a tissue-specific proteasome inhibitor, which has anticancer, anti-inflammatory, and anti-angiogenesis activities. Gambogic acid induces LRIG1 (leucine-rich repeat and Ig-like domain-containing-1) upregulation, which is responsible for EGFR (epidermal growth factor receptor) degradation and its downstream Akt/mTORC1 inhibition.
    Targets: HSP (e.g. HSP90) | Bcr-Abl | EGFR | Akt | mTOR | NF-kB | VEGFR | Src | ROS | AMPK | P450 (e.g. CYP17) | JNK
    In vitro:
    Cell Biochem Biophys. 2013 Sep;67(1):199-206.
    Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis.[Pubmed: 23436279]
    Ovarian cancer is one human malignancy which has response portly to doxorubicin. The anti-cancer activity of gambogic acid has been tested in in vitro and in vivo studies.
    In this study, we showed that gambogic acid, a natural compound, could potentiate the anticancer activity of doxorubicin in ovarian cancer through ROS-mediated apoptosis. Platinum-resistant human ovarian cancer cell line (SKOV-3) was treated with gambogic acid, doxorubicin, or the combination of both to investigate cell proliferation and apoptosis. We found that the combination of gambogic acid and doxorubicin causes synergistic loss of cell viability in SKOV-3 cells and this synergistic effect correlated with increased cellular ROS accumulation. Moreover, in vivo results showed that gambogic acid and doxorubicin combination resulted in a synergistic suppressing effect on tumor growth in ovarian cancer mice model.
    Taken together, the results suggested that doxorubicin in combination with gambogic acid might provide a promising therapeutic strategy to enhance chemosensitivity of ovarian cancer to doxorubicin.
    Cancer Res. 2008 Mar 15;68(6):1843-50.
    Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling.[Pubmed: 18339865 ]
    Gambogic acid (GA), the main active compound of Gamboge hanburyi, has been previously reported to activate apoptosis in many types of cancer cell lines by targeting transferrin receptor and modulating nuclear factor-kappaB signaling pathway. Whether GA inhibits angiogenesis, which is crucial for cancer and other human diseases, remains unknown.
    Here, we found that GA significantly inhibited human umbilical vascular endothelial cell (HUVEC) proliferation, migration, invasion, tube formation, and microvessel growth at nanomolar concentration. In a xenograft prostate tumor model, we found that GA effectively inhibited tumor angiogenesis and suppressed tumor growth with low side effects using metronomic chemotherapy with GA. GA was more effective in activating apoptosis and inhibiting proliferation and migration in HUVECs than in human prostate cancer cells (PC3), suggesting GA might be a potential drug candidate in cancer therapy through angioprevention with low chemotoxicity. Furthermore, we showed that GA inhibited the activations of vascular endothelial growth factor receptor 2 and its downstream protein kinases, such as c-Src, focal adhesion kinase, and AKT.
    Together, these data suggest that GA inhibits angiogenesis and may be a viable drug candidate in antiangiogenesis and anticancer therapies.
    In vivo:
    Mediators Inflamm. 2014;2014:195327.
    Potent anti-inflammatory and antiproliferative effects of gambogic acid in a rat model of antigen-induced arthritis.[Pubmed: 24623960]
    We have previously reported a continuous activation of caspase-1 and increased interleukin (IL)-1β levels in early rheumatoid arthritis (RA). These observations raised the hypothesis that drugs targeting the IL-1β pathway, in addition to tumour necrosis factor (TNF), may be particularly effective for early RA treatment. We have recently identified gambogic acid as a promising therapeutic candidate to simultaneously block IL-1β and TNF secretion. Our main goal here was to investigate whether gambogic acid administration was able to attenuate inflammation in antigen-induced arthritis (AIA) rats.
    Gambogic acid was administered to AIA rats in the early and late phases of arthritis. The inflammatory score, ankle perimeter, and body weight were evaluated during the period of treatment. Rats were sacrificed after 19 days of disease progression and paw samples were collected for histological and immunohistochemical evaluation. We found that inflammation in joints was significantly suppressed following gambogic acid administration. Histological and immunohistochemical evaluation of treated rats revealed normal joint structures with complete abrogation of the inflammatory infiltrate and cellular proliferation.
    Our results suggest that gambogic acid has significant anti-inflammatory properties and can possibly constitute a prototype anti-inflammatory drug with therapeutic efficacy in the treatment of inflammatory diseases such as RA.
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 1.5905 mL 7.9523 mL 15.9046 mL 31.8091 mL 39.7614 mL
    5 mM 0.3181 mL 1.5905 mL 3.1809 mL 6.3618 mL 7.9523 mL
    10 mM 0.159 mL 0.7952 mL 1.5905 mL 3.1809 mL 3.9761 mL
    50 mM 0.0318 mL 0.159 mL 0.3181 mL 0.6362 mL 0.7952 mL
    100 mM 0.0159 mL 0.0795 mL 0.159 mL 0.3181 mL 0.3976 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    Isogambogenin; Isogambogenin CFN92086 173938-23-3 C38H46O7 = 614.8 5mg QQ客服:2159513211
    Desoxygambogenin; Desoxygambogenin CFN92088 173614-93-2 C38H48O6 = 600.8 5mg QQ客服:2159513211
    异新藤黄酸; Isogambogenic acid CFN92096 887923-47-9 C38H46O8 = 630.8 5mg QQ客服:3257982914
    新藤黄酸; Gambogenic acid CFN92097 173932-75-7 C38H46O8 = 630.8 10mg QQ客服:1413575084
    藤黄酸; Gambogic acid CFN90172 2752-65-0 C38H44O8 = 628.75 20mg QQ客服:2159513211
    新藤黄酸; Neogambogic acid CFN90175 93772-31-7 C38H46O9 = 646.77 20mg QQ客服:2159513211
    Gambogin; Gambogin CFN92089 173792-67-1 C38H46O6 = 598.8 5mg QQ客服:1413575084
    异藤黄酸; Isogambogic acid CFN92098 149655-52-7 C38H44O8 = 628.8 5mg QQ客服:1413575084
    9R-10alpha-羟基表藤黄酸; 9R-10alpha-Hydroxyepigambogic acid CFN92099 1097882-33-1 C38H46O9 = 646.8 5mg QQ客服:2056216494
    9S-10alpha-羟基表藤黄酸; 9S-10alpha-Hydroxyepigambogic acid CFN92100 1164201-85-7 C38H46O9 = 646.8 5mg QQ客服:2159513211





    在线QQ1: 2056216494 ; QQ2: 3257982914


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产